MedCity News November 17, 2024
Frank Vinluan

Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.

Success rates in drug research for common diseases is low, and one reason for that could be perspective. Science has approached each common disorder as a single disease affecting a large population of patients. But John Mendlein, executive chairman and interim CEO of startup Vesalius Therapeutics, says a deeper look reveals that a single disease is actually many different diseases, each one with different biology that can be analyzed and potentially targeted with a novel medicine.

Vesalius is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
Related Articles:
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
PBM reform dropped in Congress' funding package
2025 and Beyond: Key Trends to Watch in Pharmacy

Share This Article